SI-BONE Posts 8-Cent Q3 Loss Per Share
SIBN sits 80% above its 52-week low of $11.48 on elevated volume (2.3× avg).
Summary
SI-BONE reported a third-quarter loss of 8 cents per share, or $3.62 million, on revenue of $55.7 million. That follows Q2 2026 revenue of $56 million, up 15.2% and ahead of estimates, with a narrower net loss — so the top-line trend was improving into this print. The headline gives no guidance and no comparison to consensus, so the 8-cent loss alone doesn't tell you whether the quarter beat or missed. The stock is a roughly $900 million market cap name, meaning a single quarter's surprise can move it sharply. Context worth keeping in mind: the company disclosed a voluntary recall of 98 iFuse TORQ implants on September 11 over a packaging sterility failure, and won FDA 510(k) clearance for iFuse Granite Onyx on September 28. Any updated outlook will determine direction.
At the time of this announcement, SIBN was trading at $20.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $906.2M. The 52-week trading range was $11.48 to $22.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.